Sector
PharmaceuticalsOpen
₹605.7Prev. Close
₹593.55Turnover(Lac.)
₹6.6Day's High
₹606.9Day's Low
₹596.4552 Week's High
₹99952 Week's Low
₹567.15Book Value
₹563.58Face Value
₹10Mkt Cap (₹ Cr.)
215.99P/E
8.73EPS
69.27Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 3.57 | 3.57 | 3.57 | 3.57 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 173.92 | 151.23 | 152.48 | 133.07 |
Net Worth | 177.49 | 154.8 | 156.05 | 136.64 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 96.56 | 70.57 | 92.47 | 95.47 |
yoy growth (%) | 36.82 | -23.67 | -3.13 | 23.96 |
Raw materials | -50.06 | -40.02 | -53.57 | -48.67 |
As % of sales | 51.84 | 56.71 | 57.93 | 50.98 |
Employee costs | -10.18 | -9.7 | -8.56 | -6.75 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 17.59 | 9.11 | 18.04 | 24.88 |
Depreciation | -1.98 | -2 | -1.56 | -1.55 |
Tax paid | -4.05 | -1.98 | -5.6 | -8.26 |
Working capital | 11.57 | 22.79 | -3.33 | 10.21 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 36.82 | -23.67 | -3.13 | 23.96 |
Op profit growth | 199.58 | -65.14 | -34.33 | 41.59 |
EBIT growth | 92.21 | -49.25 | -27.44 | 42.53 |
Net profit growth | 90.09 | -42.7 | -23.62 | 31.45 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,669.3 | 93.52 | 4,00,520.99 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,613.75 | 79.48 | 1,75,574.28 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,512.75 | 25.39 | 1,22,186 | 1,485.4 | 1.06 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,321.2 | 20.61 | 1,10,263.53 | 1,200.7 | 0.61 | 5,546.3 | 345.76 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,225.7 | 57.29 | 1,09,167.44 | 474 | 0.99 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Whole-time Director
Girish Dhameja
Director & CFO
Sushma Shashi Kadkade
Independent Director
Saurabh Shah
Independent Director
Malay Doshi
Non Executive Director
Rajendrasinh Rana
Company Sec. & Compli. Officer
Dhwani Desai
Independent Director
Pooja Hindia
SF-206 Silver Oak Complex,
BPC Road,
Gujarat - 390020
Tel: 91-022-2500 5245/46
Website: http://www.corallab.com
Email: [email protected]
C-101 247 Park,
L B S Marg, Vikhroli West,
Mumbai-400083
Tel: 91-22-49186000
Website: www.linkintime.co.in
Email: [email protected]
Summary
Coral Laboratories Limited (CLL) was established in February, 1997. Carol Labs are into manufacturing of Generic Branded, Nutraceuticals, OTC and Herbal Medicines. The Company produces various pharmac...
Read More
Reports by Coral Laboratories Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.